Company Encyclopedia
View More
name
Yunnan Baiyao
000538.SZ
Yunnan Baiyao Group Co.,Ltd engages in the pharmaceutical business in China. The company offers health products; drugs; chemical raw materials, chemical preparations, sales of chemical raw materials, chemical preparations, Chinese patent medicines, Chinese herbal medicines, biological products, medical devices, health food, food, beverages, special labor protection products, production and sales of daily chemical products, cosmetics and outdoor products; production and sales of rubber plasters, plasters, disinfection products, electronic and digital product; information technology, science and technology and economic and technical consulting services; import and export of goods; property management; wholesale and retail of medicine; logistics and distribution; and tea products. Yunnan Baiyao Group Co., Ltd. was founded in 1902 and is based in Kunming, China.
3.157 T
000538.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking4/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE12.96%B
    • Profit Margin12.75%B
    • Gross Margin28.71%C
  • Growth ScoreC
    • Revenue YoY3.65%C
    • Net Profit YoY21.01%B
    • Total Assets YoY-4.08%D
    • Net Assets YoY-1.79%D
  • Cash ScoreC
    • Cash Flow Margin784.11%B
    • OCF YoY3.65%C
  • Operating ScoreB
    • Turnover0.75B
  • Debt ScoreB
    • Gearing Ratio25.36%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Yunnan Baiyao Group Co.,Ltd Announces Changes to Its Board

    Yunnan Baiyao Group Co.,Ltd held its 2nd Extraordinary General Meeting of 2025 on 10 November 2025, during which the following proposal(s) was/were approved: Election of non-independent directors, cumulative voting system applicable: Zhang Wenxue, non-independent director, Dong Ming, non-independent director, Guo Xin, non-independent director, You Guanghui, non-independent director, Xie Yunshan, non-independent director, Shangguan Changchuan, non-independent director, Li Ke, non-independent director and Election of independent directors, cumulative voting system applicable: Liu Guo'en, independent director, Na Chaohong, independent director, Hu Mingxing, independent director and Cao Yangfeng, independent director.

    marketscreener·
    SZ
    000538
    +0.36%
    marketscreener·
    SZ
    000538
    +0.36%

    Yunnan Baiyao elects Zhang Wenxue as chairman

    Yunnan Baiyao elects Zhang Wenxue as chairman

    marketscreener·
    SZ
    000538
    +0.36%
    marketscreener·
    SZ
    000538
    +0.36%

    "Artificial Intelligence + Healthcare" welcomes new policies, multiple listed companies are expected to benefit

    On November 4th, the National Health Commission issued the "Implementation Opinions on Promoting and Regulating the Development of 'Artificial Intelligence + Healthcare' Applications." Several A-share companies, such as SWS Medical, Yunnan Baiyao, and EASEPAL, have already laid out plans in the "Artificial Intelligence + Healthcare" field. The implementation opinions clarify the direction of industry support and key application areas, bringing new business expansion opportunities to related listed companies and aiding in performance growth

    Wallstreetcn·
    SZ
    000538
    +0.36%
    SZ
    002614
    +2.63%
    SH
    688410
    +2.03%
    Wallstreetcn·
    SZ
    000538
    +0.36%
    SZ
    002614
    +2.63%
    SH
    688410
    +2.03%

    Yunnan Baiyao's Attributable Profit Increases Marginally in Q3

    Yunnan Baiyao's Attributable Profit Increases Marginally in Q3

    marketscreener·
    SZ
    000538
    +0.36%
    marketscreener·
    SZ
    000538
    +0.36%

    Goneo Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025

    Goneo Group Co., Ltd. reported its earnings for the nine months ending September 30, 2025. Sales decreased to CNY 12,197.68 million from CNY 12,603.04 million year-over-year. Net income also fell to CNY 2,978.82 million from CNY 3,263.4 million. Basic and diluted earnings per share from continuing operations were both CNY 1.65, down from CNY 1.81 a year ago.

    marketscreener·
    SH
    603195
    -0.35%
    marketscreener·
    SH
    603195
    -0.35%
    © 2025 Longbridge｜Disclaimer